MIT sugars research affecting bypass patients, drug industry
A young MIT professor’s basic research on complex sugars has led to a cascade of potential medical applications that could, for example, significantly improve outcomes for patients undergoing major operations such as heart bypass surgery and impact a multi-billion dollar drug industry. In the online edition of the Proceedings of the National Academy of Sciences for the week of January 13, a team led by the professor, Ram Sasisekharan, reports the creation of designer drugs for preventing the blood clots that can cause strokes and heart disease during surgery. The resulting drugs have major advantages over the conventional form they are based on, which has an annual market of $2-3 billion. Further, an additional drug based on Sasisekharan’s work is presently in Phase III clinical trials for heart bypass patients.